2025
$1.61
▼
OE = CFO − ΔWC − SBC − maintenance capex. CFO=$12.3M; WC cash effect=$(99.6)M (AR -2.2, inventories -23.5, other current assets +1.4, AP & accrued -75.3, the last including ~$57M paid on the 2024 tissue-sale tax liability); SBC=$3.8M; capex=$88.8M, growth capex=$6.7M (capex/revenue mean ~3.9% x revenue +$171.8M) so maintenance capex=$82.1M; OE=$26.0M; diluted shares=16.169M; OE/sh=$1.61. Includes ~$23M R&W insurance recovery offset by integration/severance charges. Reconciliation NI+D&A+noncash checked to CFO (gap resolved: loss on assets +7.9). Source: FY2025 10-K, accession 0001441236-26-000007.
2024
-$4.33
▼
OE = CFO − ΔWC − SBC − maintenance capex. Consolidated incl. tissue (sold Nov 1 2024) and Augusta (acquired May 2024) - transformation year, excluded from anchor. CFO=$61.4M; WC cash effect=+$21.6M (AR -87.2, inv +12.4, other -2.5, AP&accrued +98.9); SBC=$5.6M; capex=$116.6M, growth capex=$9.7M so maintenance capex=$106.9M; OE=$(72.7)M; diluted shares=16.781M; OE/sh=$(4.33). Source: FY2025 10-K (comparative), accession 0001441236-26-000007; also FY2024 10-K 0001504337-25-000005.
2023
$7.31
▼
OE = CFO − ΔWC − SBC − maintenance capex. Consolidated incl. tissue business later divested (different business than today). CFO=$190.7M; WC cash effect=$(17.8)M (AR -1.3, inv +4.0, other +0.8, AP&accrued -21.3); SBC=$9.9M; capex=$73.7M, growth capex=$0.1M so maintenance capex=$73.6M; OE=$125.0M; diluted shares=17.091M; OE/sh=$7.31. Source: FY2025 10-K comparative, accession 0001441236-26-000007; FY2023 10-K 0001504337-24-000010.
2022
$7.57
▼
OE = CFO − ΔWC − SBC − maintenance capex. Consolidated incl. tissue (later divested). CFO=$150.2M; WC cash effect=$(14.0)M (AR -16.9, inv -46.3, AP&accrued +49.2); SBC=$12.7M; capex=$33.5M, growth capex=$12.0M (mean capex/rev ~3.9% x revenue +$307.5M) so maintenance capex=$21.5M; OE=$130.0M; diluted shares=17.181M; OE/sh=$7.57. Source: FY2022 10-K accession 0001504337-23-000008 (as restated in later filings).
2021
$4.32
▼
OE = CFO − ΔWC − SBC − maintenance capex. Consolidated incl. tissue (later divested). CFO=$96.4M; WC cash effect=$(23.6)M (AR -5.3, inv -20.2, AP&accrued +1.9); SBC=$9.1M; capex=$38.4M, growth capex=$0 (revenue declined) so maintenance capex=$38.4M; OE=$72.5M; diluted shares=16.767M; OE/sh=$4.32. Source: FY2021 10-K accession 0001504337-22-000008.
2020
$11.19
▼
OE = CFO − ΔWC − SBC − maintenance capex. Consolidated incl. tissue (later divested). CFO=$247.0M; WC cash effect=+$9.7M (AR +6.1, inv +18.1, employee liabs -2.5, AP&accrued -12.0); SBC=$10.5M; capex=$39.6M treated entirely as maintenance (prior-year revenue not pulled) ; OE=$187.2M; diluted shares=16.724M; OE/sh=$11.19. COVID-year tissue demand spike. Source: FY2020 10-K accession 0001504337-21-000009.
Owner's earnings per share by fiscal year, most recent first. Tap a row to see how that figure was calculated, including the source filing.